Dawn of Early Detection Healthcare
Total Page:16
File Type:pdf, Size:1020Kb
Dawn of early OVERVIEW EARLY DETECTION THE BARRIERdetection healthcare BREAKING THROUGH T H E T E C H N A N O X A R C NANOX BENEFITS R S N A 2 0 2 0 OPINIONS O U R P L A N BUSINESS MODEL DEPLOYMENTS NANOX CLOUD FDA PARTNERSHIPS Investor Presentation T E A M S U M M A R Y April 2021 1 Forward-Looking Information Statement also affect these forward-looking statements. The reader should not place undue Statements contained in this presentation concerning expectations, beliefs, plans, reliance on any forward-looking statements included in this presentation. These objectives, goals, strategies, future events or performance and underlying statements speak only as of the date made and Nanox is under no obligation and assumptions and other statements that are other than statements of historical fact disavows any obligation to update or revise such statements as a result of any are “forward-looking statements.” These statements often include words such as event, circumstances or otherwise, unless required by applicable legislation or “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “target,” “project,” regulation. “forecast,” “seek,” “will,” “may,” “should,” “could,” “would” or similar expressions. Although Nanox believes that the expectations and assumptions reflected in these These risks and uncertainties are described more fully under the caption ”Risk statements are reasonable, these expectations or forecasts of future performance Factors” in the Company’s registration statement relating to this offering and other may not prove to be correct. Forward-looking statements are subject to many risks filings with the Securities and Exchange Commission. Other risks and uncertainties of and uncertainties, and actual results may differ materially from the results discussed which the Company is not currently aware may also affect Company’s forward- in forward-looking statements. The following are among the important factors that looking statements. The reader should not place undue reliance on any forward- could cause actual results to differ materially from the forward-looking statements: looking statements included in this presentation. These statements speak only as of risks related to Nanox’s ability to successfully demonstrate the feasibility of its the date made and the Company is under no obligation and disavows any technology for commercial applications; Nanox’s expectations regarding the obligation to update or revise such statements as a result of any event, necessity of, timing of filing for, and receipt and maintenance of, regulatory circumstances or otherwise, unless required by applicable legislation or regulation. clearances or approvals regarding its X-Ray source technology and the Nanox.ARC from regulatory agencies worldwide and its ongoing compliance with applicable Market and Industry Data and Customer Information quality standards and regulatory requirements; Nanox’s ability to enter into and This presentation has been prepared by Nanox and includes market data and other maintain commercially reasonable arrangements with third-party manufacturers information from sources believed by the company to be reliable. For example, and suppliers to manufacture the Nanox.ARC; the market acceptance of the industry and market data, including Nanox’s own research, and surveys or industry Nanox.ARC and the proposed pay-per-scan business model; Nanox’s expectations publications and surveys as well as public information about Nanox’s customers and regarding collaborations with third-parties and their potential benefits; Nanox’s discussion with them. Some data are also based on Nanox’s good-faith estimates, ability to conduct business globally; the impact of general economic conditions, which are derived from Nanox’s review of internal sources as well as the other general conditions in the medical technology and imaging industries; the impact of sources described above. Although Nanox believes these sources are reliable, the COVID-19 pandemic on the Company's business operations; changes in the Nanox has not independently verified the information is accurate and complete. As global and regional regulatory environments in the jurisdictions in which Nanox does a result, you should be aware that market share, ranking and other similar data set or plans to do business; and market volatility, fluctuations in costs and changes to forth in this presentation, and estimates and beliefs based on such data may not be the competitive environment, among others. Consequently, actual future results reliable. may differ materially from the anticipated results expressed in the forward-looking statements. Other risks and uncertainties of which Nanox is not currently aware may 2 Nanox at a glance The What Unmet need Game changing tech Disruptive business model Nanox aims to build a Large deficit of medical Nanox’s novel digital X-Ray source Executed contracts for 5,150 units ILLUSTRATIVE MODEL global infrastructure for imaging systems due to high replaces an analog X-Ray that has been pending regulatory and other medical imaging system costs used for over 100 years and enables approvals POTENTIAL ANNUAL RECURRING REVENUE ASSUMING THE 5,150 significant cost reduction CONTRACTED UNITS ARE DEPLOYED AND OPERATIONAL Medical Screening as a Service $1,194,000,000 Utilizing innovative, patent (MSaaS) opens a recurring protected and disruptive Developing a new breed of medical revenue model that has the technology, Nanox can offer imaging infrastructure that can be potential to provide substantial medical technology that potentially deployed in mass due to revenues expands access, resulting in significantly lower costs and a small $397,000,000 better outcomes and lower footprint, coupled with a radiology costs. services cloud platform $139,000,000 Planning global mass 7 20 60 SCANS PER DAY Upcoming Milestones deployment of 15,000 systems with a Pay-per- Until today, technology was Scan subscription the barrier to medical model imaging availability. We are targeting several near-term value catalysts such as FDA approvals and commercialization See slide 27 for full detail and assumptions Nanox believes it has broken that barrier. Strategic partner deals signed First units shipped by Q1 2022 Concept device. Manufacturing ramp-up FDA single source and multi For educational purposes With global execution source device approvals 2/3 of the world’s population Global deployments only. expected to start this year has no meaningful access to Nanox invites partners to join medical imaging. 15,000 units the potentially next Strategic Shareholders deployed and operational revolution in Weeks and months of wait 2021 preventive healthcare. times for radiology Exceptionally seasoned execution diagnostics results. 2022-2024 team Healthcare and technology veterans from companies like GE, Philips, and highly successful, game-changing technology entrepreneurs 3 Preventive screening OVERVIEW EARLY DETECTION Early detection is key to THE BARRIER BREAKING THROUGH T H E T E C H preventive healthcare. N A N O X A R C NANOX BENEFITS R S N A 2020 Treatable conditions, such as cancer, cardiovascular OPINIONS failures and others are often diagnosed too late. O U R P L A N BUSINESS MODEL DEPLOYMENTS NANOX CLOUD FDA PARTNERSHIPS T E A M S U M M A R Y 4 Early detection remains theoretical OVERVIEW EARLY DETECTION 2/3 of the world’s THE BARRIER BREAKING THROUGH T H E T E C H population have no N A N O X A R C NANOX BENEFITS meaningful access to R S N A 2020 OPINIONS medical imaging O U R P L A N BUSINESS MODEL DEPLOYMENTS The majority of the remaining 1/3 suffer NANOX CLOUD from weeks and months of wait time for FDA PARTNERSHIPS access to medical scanners and T E A M diagnostic results. S U M M A R Y 5 Why? OVERVIEW EARLY DETECTION Medical imaging THE BARRIER BREAKING THROUGH T H E T E C H systems are too N A N O X A R C NANOX BENEFITS expensive and R S N A 2020 OPINIONS complex for mass O U R P L A N BUSINESS MODEL deployment. DEPLOYMENTS NANOX CLOUD FDA PARTNERSHIPS T E A M S U M M A R Y 6 The key inhibitor OVERVIEW EARLY DETECTION X-Ray source technology THE BARRIER BREAKING THROUGH T H E T E C H has not changed since its N A N O X A R C NANOX BENEFITS discovery over 120 years R S N A 2020 OPINIONS ago O U R P L A N BUSINESS MODEL DEPLOYMENTS NANOX CLOUD FDA PARTNERSHIPS T E A M S U M M A R Y 7 Wilhelm Conrad Röntgen The hot cathode OVERVIEW EARLY DETECTION Current day X-Ray tube THE BARRIER Analog X-Ray source BREAKING THROUGH T H E T E C H Heats up a metal filament to 2,000° Celsius to produce the N A N O X A R C electron streams necessary for NANOX BENEFITS X-Ray emission R S N A 2020 OPINIONS Electrons O U R P L A N BUSINESS MODEL DEPLOYMENTS NANOX CLOUD FDA PARTNERSHIPS T E A M S U M M A R Y 8 Main contributor to high-cost of imaging systems OVERVIEW EARLY DETECTION THE BARRIER BREAKING THROUGH T H E T E C H N A N O X A R C NANOX BENEFITS R S N A 2020 OPINIONS O U R P L A N BUSINESS MODEL The legacy DEPLOYMENTS analog X-Ray NANOX CLOUD FDA source PARTNERSHIPS Requires extremely high-voltage, complex T E A M mechanics and special cooling to produce the S U M M A R Y electrons needed for X-Ray emission, resulting in an average $150,000 cost for the source alone 9 The Nanox paradigm OVERVIEW EARLY DETECTION Driving higher THE BARRIER rates of medical BREAKING THROUGH Which we expect will prevention through T H E T E C H enable significantly early-detection. N A N O X A R C higher availability of NANOX BENEFITS Will result in lower cost R S N A 2020 imaging services A